In 2022, Jeffrey Todd became one of more than 30,000 U.S. adults to contract mpox. After noticing his first lesion, he found online images of mpox rashes resembling his blemish. He assumed the rash would disappear by morning.
Instead, over two days, more bumps appeared on his right arm and back. A lesion also emerged on his neck. The spots itched, and he experienced fatigue, backaches, and shooting leg pains.
Todd was eventually tested for mpox and started antiviral treatment. However, the process involved a long and frustrating journey of self-advocacy. After 28 days in quarantine, he resolved to raise awareness about mpox. Todd hoped to prevent others from enduring the same ordeal.
Since 2022, mpox cases in non-endemic countries have dropped. Yet, mpox still harms tens of thousands worldwide. The World Health Organization (WHO) will convene a meeting this month to evaluate whether mpox still constitutes a global emergency.